SAHPRA added in a statement that the approval was subject to further efficacy and safety surveillance of the vaccine in the country, including against the dominant local coronavirus variant.
JOHANNESBURG: South Africa's drugs regulator SAHPRA said on Tuesday that it had approved a "section 21" emergency use application for the COVID-19 vaccine developed by Pfizer and BioNTech.
SAHPRA added in a statement that the approval was subject to further efficacy and safety surveillance of the vaccine in the country, including against the dominant local coronavirus variant.
Comments
Comments are closed for this article.